-
1
-
-
0032584208
-
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
-
COI: 1:CAS:528:DyaK1cXitlKjsLY%3D, PID: 9520411
-
Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS. 1998;95(7):3597–602.
-
(1998)
PNAS
, vol.95
, Issue.7
, pp. 3597-3602
-
-
Yasuda, H.1
Shima, N.2
Nakagawa, N.3
-
2
-
-
7344233085
-
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
-
COI: 1:CAS:528:DyaK1cXjs1Oru70%3D, PID: 9603945
-
Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363–7.
-
(1998)
J Biol Chem
, vol.273
, Issue.23
, pp. 14363-14367
-
-
Emery, J.G.1
McDonnell, P.2
Burke, M.B.3
-
3
-
-
0031005576
-
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
-
COI: 1:CAS:528:DyaK2sXislCgtLc%3D, PID: 9108485
-
Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.
-
(1997)
Cell
, vol.89
, Issue.2
, pp. 309-319
-
-
Simonet, W.S.1
Lacey, D.L.2
Dunstan, C.R.3
-
4
-
-
57249094356
-
Pathophysiological roles of osteoprotegerin (OPG)
-
COI: 1:CAS:528:DC%2BD1MXhvFGhu7w%3D, PID: 18707795
-
Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88(1):1–17.
-
(2009)
Eur J Cell Biol
, vol.88
, Issue.1
, pp. 1-17
-
-
Reid, P.1
Holen, I.2
-
5
-
-
0037086077
-
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
-
COI: 1:CAS:528:DC%2BD38XisVSisLw%3D, PID: 11912131
-
Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62(6):1619–23.
-
(2002)
Cancer Res
, vol.62
, Issue.6
, pp. 1619-1623
-
-
Holen, I.1
Croucher, P.I.2
Hamdy, F.C.3
Eaton, C.L.4
-
6
-
-
4043138669
-
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis
-
COI: 1:CAS:528:DC%2BD2cXmt1Kqtro%3D, PID: 15567943
-
Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86(3):269–79.
-
(2004)
Breast Cancer Res Treat
, vol.86
, Issue.3
, pp. 269-279
-
-
Neville-Webbe, H.L.1
Cross, N.A.2
Eaton, C.L.3
-
7
-
-
0037374460
-
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells
-
COI: 1:CAS:528:DC%2BD3sXhs1agtb0%3D, PID: 12615702
-
Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63(5):912–6.
-
(2003)
Cancer Res
, vol.63
, Issue.5
, pp. 912-916
-
-
Shipman, C.M.1
Croucher, P.I.2
-
8
-
-
24644435593
-
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival?
-
COI: 1:CAS:528:DC%2BD2MXpvV2gs7c%3D, PID: 16155791
-
Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207–15.
-
(2005)
Breast Cancer Res Treat
, vol.92
, Issue.3
, pp. 207-215
-
-
Holen, I.1
Cross, S.S.2
Neville-Webbe, H.L.3
-
9
-
-
33645221176
-
Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
-
COI: 1:CAS:528:DC%2BD28Xjt1Gqtbw%3D, PID: 16287088
-
Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118(8):1901–8.
-
(2006)
Int J Cancer
, vol.118
, Issue.8
, pp. 1901-1908
-
-
Cross, S.S.1
Yang, Z.2
Brown, N.J.3
-
10
-
-
79953323463
-
Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties
-
COI: 1:CAS:528:DC%2BC3MXnt1ensrw%3D, PID: 21255246
-
Benslimane-Ahmim Z, Heymann D, Dizier B, et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost. 2011;9(4):834–43.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.4
, pp. 834-843
-
-
Benslimane-Ahmim, Z.1
Heymann, D.2
Dizier, B.3
-
11
-
-
13344285339
-
Identification and characterization of a new member of the TNF family that induces apoptosis
-
COI: 1:CAS:528:DyaK28XhtF2iug%3D%3D
-
Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immun. 1995;3(6):673–82.
-
(1995)
Immun
, vol.3
, Issue.6
, pp. 673-682
-
-
Wiley, S.R.1
Schooley, K.2
Smolak, P.J.3
-
12
-
-
17544367410
-
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
-
COI: 1:CAS:528:DyaK28XjtlGjtrc%3D, PID: 8663110
-
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687–90.
-
(1996)
J Biol Chem
, vol.271
, Issue.22
, pp. 12687-12690
-
-
Pitti, R.M.1
Marsters, S.A.2
Ruppert, S.3
Donahue, C.J.4
Moore, A.5
Ashkenazi, A.6
-
13
-
-
78149284013
-
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
-
COI: 1:CAS:528:DC%2BC3cXht1ajtbvI, PID: 20881962
-
Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102.
-
(2010)
Nature
, vol.468
, Issue.7320
, pp. 98-102
-
-
Schramek, D.1
Leibbrandt, A.2
Sigl, V.3
-
14
-
-
78149284767
-
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
-
COI: 1:CAS:528:DC%2BC3cXht1ajur7J, PID: 20881963
-
Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–7.
-
(2010)
Nature
, vol.468
, Issue.7320
, pp. 103-107
-
-
Gonzalez-Suarez, E.1
Jacob, A.P.2
Jones, J.3
-
15
-
-
79952193038
-
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
-
COI: 1:CAS:528:DC%2BC3MXhvFKltL8%3D, PID: 21326202
-
Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–53.
-
(2011)
Nature
, vol.470
, Issue.7335
, pp. 548-553
-
-
Tan, W.1
Zhang, W.2
Strasner, A.3
-
16
-
-
79953305288
-
Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study
-
COI: 1:CAS:528:DC%2BC3MXnt1egurw%3D, PID: 21284802
-
Vik A, Mathiesen EB, Brox J, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost. 2011;9(4):638–44.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.4
, pp. 638-644
-
-
Vik, A.1
Mathiesen, E.B.2
Brox, J.3
-
17
-
-
77953774003
-
Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population—the Tromso study
-
COI: 1:CAS:528:DC%2BC3cXnsVegtLk%3D, PID: 20128863
-
Vik A, Mathiesen EB, Johnsen SH, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population—the Tromso study. J Thromb Haemost. 2010;8(5):898–905.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.5
, pp. 898-905
-
-
Vik, A.1
Mathiesen, E.B.2
Johnsen, S.H.3
-
18
-
-
61449257635
-
Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness
-
PID: 19091545
-
Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.
-
(2009)
Eur J Cancer
, vol.45
, Issue.7
, pp. 1218-1231
-
-
Larsen, I.K.1
Småstuen, M.2
Johannesen, T.B.3
-
19
-
-
2442492972
-
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease
-
COI: 1:CAS:528:DC%2BD2cXjs1eisrk%3D, PID: 15117849
-
Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175–80.
-
(2004)
Circulation
, vol.109
, Issue.18
, pp. 2175-2180
-
-
Kiechl, S.1
Schett, G.2
Wenning, G.3
-
20
-
-
72049092419
-
Denosumab, Osteoporosis, and prevention of fractures
-
COI: 1:CAS:528:DC%2BD1MXhsFWgs7fI, PID: 19940304
-
Kiechl S, Willeit J, Schett G, et al. Denosumab, Osteoporosis, and prevention of fractures. N Engl J Med. 2009;361(22):2188–91.
-
(2009)
N Engl J Med
, vol.361
, Issue.22
, pp. 2188-2191
-
-
Kiechl, S.1
Willeit, J.2
Schett, G.3
-
21
-
-
0041854146
-
Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma
-
COI: 1:CAS:528:DC%2BD3sXmsVSitbY%3D, PID: 12838418
-
Ito R, Nakayama H, Yoshida K, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 2003;443(2):146–51.
-
(2003)
Virchows Arch
, vol.443
, Issue.2
, pp. 146-151
-
-
Ito, R.1
Nakayama, H.2
Yoshida, K.3
-
22
-
-
27944448767
-
Osteoprotegerin is expressed in colon carcinoma cells
-
COI: 1:CAS:528:DC%2BD2MXht12itrnM, PID: 16309167
-
Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25(6B):3809–16.
-
(2005)
Anticancer Res
, vol.25
, Issue.6B
, pp. 3809-3816
-
-
Pettersen, I.1
Bakkelund, W.2
Smedsrød, B.3
Sveinbjørnsson, B.4
-
23
-
-
51049114701
-
OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer
-
PID: 18676739
-
De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 2008;14(15):4713–8.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.15
, pp. 4713-4718
-
-
De Toni, E.N.1
Thieme, S.E.2
Herbst, A.3
-
24
-
-
0035992402
-
Serum osteoprotegerin levels in healthy controls and cancer patients
-
COI: 1:CAS:528:DC%2BD38XmtVWhsLY%3D, PID: 12114435
-
Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2002;8(7):2306–10.
-
(2002)
Clin Cancer Res
, vol.8
, Issue.7
, pp. 2306-2310
-
-
Lipton, A.1
Ali, S.M.2
Leitzel, K.3
-
25
-
-
79954608597
-
Clinical significance of osteoprotegerin expression in human colorectal cancer
-
COI: 1:CAS:528:DC%2BC3MXkslCgt78%3D, PID: 21270110
-
Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011;17(8):2444–50.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.8
, pp. 2444-2450
-
-
Tsukamoto, S.1
Ishikawa, T.2
Iida, S.3
-
26
-
-
84866543321
-
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model
-
COI: 1:CAS:528:DC%2BC38XhtlGmtr7N, PID: 22926264
-
Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat. 2012;135(3):771–80.
-
(2012)
Breast Cancer Res Treat
, vol.135
, Issue.3
, pp. 771-780
-
-
Canon, J.1
Bryant, R.2
Roudier, M.3
Branstetter, D.G.4
Dougall, W.C.5
-
27
-
-
79955772442
-
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
-
COI: 1:CAS:528:DC%2BC3MXlslGmt7Y%3D, PID: 21559440
-
Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE. 2011;6(4):e19234.
-
(2011)
PLoS ONE
, vol.6
, Issue.4
, pp. e19234
-
-
Santini, D.1
Schiavon, G.2
Vincenzi, B.3
-
28
-
-
80052773257
-
Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis
-
Kamiya N, Suzuki H, Endo T, et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol. 2011;16(4):366–72.
-
(2011)
Int J Clin Oncol
, vol.16
, Issue.4
, pp. 336-372
-
-
Kamiya, N.1
Suzuki, H.2
Endo, T.3
-
29
-
-
84874883241
-
Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC3sXks1WgsrY%3D, PID: 23516466
-
Peng X, Guo W, Ren T, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS ONE. 2013;8(3):e58361.
-
(2013)
PLoS ONE
, vol.8
, Issue.3
, pp. e58361
-
-
Peng, X.1
Guo, W.2
Ren, T.3
-
30
-
-
14844288360
-
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
-
Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updates. 2004;7(6):345–58.
-
(2004)
Drug Resist Updates
, vol.7
, Issue.6
, pp. 345-358
-
-
Van Geelen, C.M.1
de Vries, E.G.2
de Jong, S.3
-
31
-
-
84868131986
-
Osteoprotegerin in bone metastases: mathematical solution to the puzzle
-
COI: 1:CAS:528:DC%2BC38Xhs1ansbfJ, PID: 23093918
-
Ryser MD, Qu Y, Komarova SV. Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol. 2012;8(10):e1002703.
-
(2012)
PLoS Comput Biol
, vol.8
, Issue.10
, pp. e1002703
-
-
Ryser, M.D.1
Qu, Y.2
Komarova, S.V.3
-
32
-
-
34447512931
-
Heparin induces mobilization of osteoprotegerin into the circulation
-
COI: 1:CAS:528:DC%2BD2sXotVyqsbk%3D, PID: 17598007
-
Vik A, Brodin E, Sveinbjornsson B, Hansen JB. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost. 2007;98(1):148–54.
-
(2007)
Thromb Haemost
, vol.98
, Issue.1
, pp. 148-154
-
-
Vik, A.1
Brodin, E.2
Sveinbjornsson, B.3
Hansen, J.B.4
-
33
-
-
34547574967
-
Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease
-
COI: 1:CAS:528:DC%2BD2sXnslKksLc%3D, PID: 17620507
-
Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116(4):385–91.
-
(2007)
Circulation
, vol.116
, Issue.4
, pp. 385-391
-
-
Kiechl, S.1
Schett, G.2
Schwaiger, J.3
|